AYTU BIOPHARMA, INC Derivative Liability, Current
AYTU BIOPHARMA, INC (AYTU) had Derivative Liability, Current of $3.26 million as of 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2024-05-15
- 2024-03-31: Derivative Liability, Current $3.26M.
- 2023-06-30: Derivative Liability, Current $0.00.
| Period end | Derivative Liability, Current |
|---|---|
| 2024-03-31 | $3.26M 10-Q · filed 2024-05-15 |
| 2023-06-30 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |